Four in ten EEA doctors considering quitting, says survey.
ABPI says Norgine’s support will be important during Brexit.
Britain will be in “second or third tier” of drug launches, experts warn.
UK pharma leaders are putting a brave face on Brexit – but the ‘phoney war’ is about to give way to hard-nosed negotiations
But longer-term benefits could include faster reimbursement decisions.
Other Japanese firms could scale back UK investment.
Britain could be in “second rank” of medicines access, warn MPs.